Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes
Open accessAbstract
OBJECTIVE—The degree to which chronic glycemic exposure (CGE) (fasting plasma glucose [FPG], HbA1c [A1C], duration of diabetes, age at onset of diabetes, or combinations of these) is associated with or predicts the severity of microvessel complications is unsettled. Specifically, we test whether combinations of components correlate and predict complications better than individual components. RESEARCH DESIGN AND METHODS—Correlations and predictions of CGE and complications were assessed in the Rochester Diabetic Neuropathy Study, a population-based, cross-sectional, and longitudinal epidemiologic survey of 504 patients with diabetes followed for up to 20 years. RESULTS—In multivariate analysis, A1C and duration of diabetes (and to a lesser degree age at onset of diabetes but not FPG) were the main significant CGE risk covariates for complications. A derived glycemic exposure index (GEi) correlated with and predicted complications better than did individual components. Composite or staged measures of polyneuropathy provided higher correlations and better predictions than did dichotomous measures of whether polyneuropathy was present or not. Generally, the mean GEi was significantly higher with increasing stages of severity of complications. CONCLUSIONS—A combination of A1C, duration of diabetes, and age at onset of diabetes (a mathematical index, GEi) correlates significantly with complications and predicts later complications better than single components of CGE. Serial measures of A1C improved the correlations and predictions. For polyneuropathy, continuous or staged measurements performed better than dichotomous judgments. Even with intensive assessment of CGE and complications over long times, only about one-third of the variability of the severity of complications is explained, emphasizing the role of other putative risk covariates.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A multifactorial intervention targeting glucose, hypertension, dyslipidemia, and lifestyle reduced CAN progression by 63% in a small T2D cohort in the Steno-2 trial.
“Glucose control as part of a multifactorial intervention that also targeted hypertension, dyslipidemia, and lifestyle demonstrated a 63% reduction in the rate of progression to CAN in a small T2D cohort participating in the Steno-2 trial.630”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [630]
The study description (p. 1) identifies the Rochester Diabetic Neuropathy Study, and the complication endpoints (p. 2) concern neuropathy, retinopathy, and nephropathy. Searches for Steno-2, cardiac autonomic neuropathy, multifactorial intervention, and the 63% figure found no passage reporting the claimed trial result. (LLM, conf=0.78)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 32 · Cited by 99
- Authors
- Dyck, P. J., Davies, J. L., Clark, V. M., Litchy, W. J., Dyck, P. J. B., Klein, C. J., Rizza, R. A., Pach, J. M., Klein, R., Larson, T. S., Melton, L. J., & O’Brien, P. C.
- Affiliations
- Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota
- Mayo Clinic (US)
- University of Wisconsin–Madison (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-10-01
- Volume
- 29
- Issue
- 10
- Pages
- 2282-2288
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2161984474
- Cited by
- 99
- References
- 32
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 1 · 2020: 8 · 2019: 4 · 2018: 5 · 2017: 3 · 2016: 5 · 2015: 9 · 2014: 4 · 2013: 4 · 2012: 8
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (NINDS 36797)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
- Keywords
- microvascular complications, diabetes mellitus, HbA1c, fasting blood glucose, diabetes duration, age at onset of diabetes, diabetic polyneuropathy, complication severity, risk prediction
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Blood Glucose, Cross-Sectional Studies, Diabetic Angiopathies, Diabetic Neuropathies, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Longitudinal Studies, Male, Microcirculation, Middle Aged, Prognosis, Prospective Studies, Multivariate Analysis, Age of Onset, White People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review